Strata Skin Sciences (FRA:E2O) LT-Debt-to-Total-Asset: 0.02 (As of Dec. 2025)

What is Strata Skin Sciences LT-Debt-to-Total-Asset?

Strata Skin Sciences FRA:E2O 38 LT-Debt-to-Total-Asset is 0.02 as of Dec. 2025. GuruFocus rates FRA:E2O with a GF Score™ of 38/100 and a GF Value™ of €19,176.00. The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Strata Skin Sciences's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.02.

Strata Skin Sciences's long-term debt to total assets ratio declined from Dec. 2024 (0.46) to Dec. 2025 (0.02). It may suggest that Strata Skin Sciences is progressively becoming less dependent on debt to grow their business.

Strata Skin Sciences (FRA:E2O) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Strata Skin Sciences LT-Debt-to-Total-Asset Related Terms

Strata Skin Sciences LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Strata Skin Sciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strata Skin Sciences LT-Debt-to-Total-Asset Chart

Strata Skin Sciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.17

0.16

0.36

0.46

0.02

Strata Skin Sciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.46	0.47	0.52	0.46	0.02

38GF Score

Strata Skin Sciences Inc FRA:E2O

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Strata Skin Sciences LT-Debt-to-Total-Asset Calculation

Strata Skin Sciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	0.588	/	26.065
	=	0.02

Strata Skin Sciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	0.588	/	26.065
	=	0.02

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.02 mean?

Strata Skin Sciences (FRA:E2O) has a LT-Debt-to-Total-Asset of 0.02 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Strata Skin Sciences and its competitors.

Is Strata Skin Sciences' LT-Debt-to-Total-Asset too high?

Strata Skin Sciences' current LT-Debt-to-Total-Asset is 0.02. Overall, Strata Skin Sciences has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.

How does Strata Skin Sciences' LT-Debt-to-Total-Asset compare to ODYY and NUMD?

Strata Skin Sciences' LT-Debt-to-Total-Asset of 0.02 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Strata Skin Sciences and its competitors. Strata Skin Sciences's current LT-Debt-to-Total-Asset is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Strata Skin Sciences stock overvalued right now?

Strata Skin Sciences (FRA:E2O) has a current LT-Debt-to-Total-Asset of 0.02. The stock's GF Value™ is €19,176.00, compared to a current price of €3.76 — trading 100% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.02. Strata Skin Sciences' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Strata Skin Sciences (FRA:E2O), the current LT-Debt-to-Total-Asset is 0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strata Skin Sciences (FRA:E2O) Overvalued in 2026?

Based on GuruFocus' analysis, Strata Skin Sciences stock appears to be undervalued. The current stock price of €3.76 is trading 100% below its estimated GF Value™ of €19,176.00.

Key valuation signals for FRA:E2O:

LT-Debt-to-Total-Asset: 0.02
GF Value™: €19,176.00 vs. price of €3.76 (100% below fair value)
GF Score™: 38/100 with 4 warning signs

No single metric tells the full story. See the FRA:E2O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Strata Skin Sciences Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies ODYY NUMD PFSA NUWE ESMC RBOT AEMD VYCO VTAK ALURD ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Other Exchanges SSKN:USA

Address 5 Walnut Grove Drive, Suite 140, Horsham, PA, USA, 19044

Website https://www.strataskinsciences.com

Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.

38GF Score

Get the complete analysis for FRA:E2O

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.76

Price

€19,176.00

GF Value

View FRA:E2O Analysis

See LT-Debt-to-Total-Asset data for all stocks →